Compare SIGA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | BCYC |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.8M | 291.8M |
| IPO Year | 2016 | 2019 |
| Metric | SIGA | BCYC |
|---|---|---|
| Price | $3.12 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 549.9K | 483.4K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 19.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $170.70 | N/A |
| P/E Ratio | $24.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $3.33 |
| 52 Week High | $8.54 | $9.08 |
| Indicator | SIGA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 44.13 |
| Support Level | $3.02 | $3.33 |
| Resistance Level | $3.32 | $3.99 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 17.78 | 18.70 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.